Come Hear Inaugural Director of ARPA-H Dr. Renee Wegrzyn at the 18th Annual Non-Dilutive Funding Summit
Join hundreds of life science industry leaders at
The 18th Annual Non-Dilutive Funding Summit (NDFS)
and find out more about non-dilutive funding for your R&D,
including from newly founded agency
The Advanced Research Projects Agency for Health (ARPA-H).
Participation is FREE, registration required, space limited.
Wednesday, January 11, 2023.
What Is ARPA-H?
Some breakthrough ideas don’t get enough attention because they’re too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. ARPA-H aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will have only extramural labs, and it will facilitate research directed at solving practical problems. ARPA-H is designed to be the DARPA of human health.
Find out more about ARPA-H here—on our new website.
Meet Dr. Renee Wegrzyn, First Director of the Newly-Founded ARPA-H
Dr. Renee Wegrzyn is the inaugural director of ARPA-H. She brings to her post a distinguished record of service to the public and of achievement in the private sector.
Prior to Dr. Wegrzyn’s appointment by President Biden, she worked in the private sector as the Vice President of Business Development at Ginko Bioworks. There she worked on applications of synthetic biology to outpacing infectious diseases.
Earlier, she served as Program Manager with a $250 million portfolio in the Biological Technologies Office of the Defense Advanced Research Projects Agency (DARPA)—the organizational paradigm for the Advanced Research Projects Agency for Health. She also served as a technical advisor to the Intelligence Advanced Research Projects Activity (IARPA). At DARPA, Wegrzyn leveraged the tools of synthetic biology and gene editing to enhance biosecurity, support the domestic bioeconomy, and thwart biothreats. Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA.
Dr. Wegrzyn has also served as a Senior Advisor to the Nuclear Threat Initiative and as a member of the scientific advisory board for the National Academies Standing Committee on Biotechnology Capabilities and National Security Needs, and worked as the Senior Lead Technologist at Booz Allen Hamilton and the Leader of the Assay Development Group at Adlyfe, where her work included biosecurity and gene therapy.
She earned her BSc and PhD in Applied Biology from Georgia Tech, conducted post-doctoral research at the Center for Molecular Biology of Heidelberg University, and served as a fellow at the Center for Health Security Emerging Leaders in Biosecurity in the Bloomberg Schoolf of Public Health at the Johns Hopkins University.
Apply for One-On-One Meetings
When you register, request one-on-one meetings with FreeMind and/or with representatives of funding agencies in attendance.
Reserve Your Place Today
Participation is FREE, registration required, space limited. Sign up today – it only takes two minutes – and receive updates with additional details.
